News - 29 Jul `14Clinuvel receives takeover offer from a notorious short seller

New

Clinuvel Pharmaceuticals, drug developer for skin diseases from Melbourne, has received an unsolicited $95 million takeover offer from a controversial biotech company Retrophin, soon after sudden passing of Clinuvel's long time director Jack Wood. 

On behalf of VRF management, we offer our sincere condolences to Jack's wife and family. Jack Wood was a remarkable person with a vision, big heart and brilliant sense of humor. Clinuvel is awaiting clearance from the European drug regulator for the use of its drug Scenesse in the treatment of a rare skin disease Erythropoietic Protoporphyria and potentially, in vitiligo. 

Once a notorious short seller with loud public pressure, Reptophin's CEO Martin Shkreli now aims at drugs for ultra-rare and dangerous conditions. Clinuvel has appointed an advisory firm in the defense against the hostile offer.

      FAQOther Questions

      • How long does it take to treat vitiligo?

        Treatment results will vary by person and type of vitiligo. The rule of thumb is that you will need to allow at least 3 to 6 months before you begin to see results from any trea...

      • Does halo nevi affect vitiligo development?

        Halo nevi — nevi with an depigmented circle around it, usually on the trunk — are about 10x more common in vitiligo patients than in the general population, especially in childr...

      • Shall I take vitamin D for my vitiligo?

        In Brief Vitamin D plays a central role in the prevention of different inflammatory and chronic diseases. Consuming 1,000–4,000 IU (25–100 mcg) of vitamin D3 daily should be id...